Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1, First in Human Study of Adenovirally Transduced Autologous Macrophages Engineered to Contain an Anti-HER2 Chimeric Antigen Receptor in Subjects With HER2 Overexpressing Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04660929
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:02.151285+00:00
Published At
2024-12-18T00:00:00+00:00
Record Updated At
2024-12-18
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["HER2-positive", "Adenocarcinoma", "Bile Duct Cancer", "Biliary Tract Cancer", "Bladder Cancer", "Breast Cancer", "Breast Neoplasm", "Carcinoma, Ductal", "Carcinoma, Hepatocellular", "Cancer", "Lung Cancer, Non-Small-Cell", "Carcinoma, Ovarian Epithelial", "Carcinoma, Small Cell", "Carcinoma, Squamous", "Carcinoma, Transitional Cell", "Colorectal Cancer", "Esophagogastric Junction Neoplasms", "Inflammatory Breast Cancer", "Stomach Neoplasms", "Malignant Neoplasms", "Ovarian Neoplasms", "Pancreatic Cancer", "HER2-positive Solid Tumors", "HER2-positive Breast Cancer", "HER2-positive Gastric Cancer", "HER-2 Protein Overexpression", "HER-2 Gene Amplification", "Prostate Cancer", "Head and Neck Cancer", "Endometrial Cancer", "Lung Cancer, Small Cell"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-12-18"
protocolSection.identificationModule.nctId
"NCT04660929"
protocolSection.identificationModule.officialTitle
"A Phase 1, First in Human Study of Adenovirally Transduced Autologous Macrophages Engineered to Contain an Anti-HER2 Chimeric Antigen Receptor in Subjects With HER2 Overexpressing Solid Tumors"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • HER2-positive (protocolSection.conditionsModule.conditions)
  • Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Bile Duct Cancer (protocolSection.conditionsModule.conditions)
  • Biliary Tract Cancer (protocolSection.conditionsModule.conditions)
  • Bladder Cancer (protocolSection.conditionsModule.conditions)
  • Breast Cancer (protocolSection.conditionsModule.conditions)
  • Breast Neoplasm (protocolSection.conditionsModule.conditions)
  • Carcinoma, Ductal (protocolSection.conditionsModule.conditions)
  • Carcinoma, Hepatocellular (protocolSection.conditionsModule.conditions)
  • Cancer (protocolSection.conditionsModule.conditions)
  • Lung Cancer, Non-Small-Cell (protocolSection.conditionsModule.conditions)
  • Carcinoma, Ovarian Epithelial (protocolSection.conditionsModule.conditions)
  • Carcinoma, Small Cell (protocolSection.conditionsModule.conditions)
  • Carcinoma, Squamous (protocolSection.conditionsModule.conditions)
  • Carcinoma, Transitional Cell (protocolSection.conditionsModule.conditions)
  • Colorectal Cancer (protocolSection.conditionsModule.conditions)
  • Esophagogastric Junction Neoplasms (protocolSection.conditionsModule.conditions)
  • Inflammatory Breast Cancer (protocolSection.conditionsModule.conditions)
  • Stomach Neoplasms (protocolSection.conditionsModule.conditions)
  • Malignant Neoplasms (protocolSection.conditionsModule.conditions)
  • Ovarian Neoplasms (protocolSection.conditionsModule.conditions)
  • Pancreatic Cancer (protocolSection.conditionsModule.conditions)
  • HER2-positive Solid Tumors (protocolSection.conditionsModule.conditions)
  • HER2-positive Breast Cancer (protocolSection.conditionsModule.conditions)
  • HER2-positive Gastric Cancer (protocolSection.conditionsModule.conditions)
  • HER-2 Protein Overexpression (protocolSection.conditionsModule.conditions)
  • HER-2 Gene Amplification (protocolSection.conditionsModule.conditions)
  • Prostate Cancer (protocolSection.conditionsModule.conditions)
  • Head and Neck Cancer (protocolSection.conditionsModule.conditions)
  • Endometrial Cancer (protocolSection.conditionsModule.conditions)
  • Lung Cancer, Small Cell (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.